Bevacizumab and Pegylated Liposomal Doxorubicin as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer. A Multicenter, Single-Arm Phase II Trial
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Cytologically or histologically confirmed breast cancer
- Metastatic OR locally recurrent disease
- Unresectable disease
- Not amenable to radiotherapy
- Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by
conventional techniques OR ≥ 10 mm by spiral CT scan
- Measurable disease must be outside irradiated areas
- ErbB2-negative disease by immunohistochemistry (negative or 1+) or fluorescent in
situ hybridization (FISH)
- No known CNS metastases, even if previously treated
- Hormone receptor status not specified
PATIENT CHARACTERISTICS:
- Female
- Menopausal status not specified
- WHO performance status 0-1
- LVEF ≥ 55%
- Hemoglobin ≥ 10.0 g/dL
- Absolute neutrophil count ≥ 1,500/mm³
- Platelet count ≥ 100,000/mm³
- Bilirubin < 2 times upper limit of normal (ULN)
- ALT ≤ 2.5 times ULN (5 times ULN if liver metastases are present)
- Alkaline phosphatase (AP) ≤ 2.5 times ULN
- AP > 2.5 times ULN and ≤ 6 times ULN allowed if ALT ≤ 1.5 times ULN
- AP > 6 times ULN allowed if ALT normal
- Creatinine ≤ 1.5 times ULN
- Proteinuria < 2+ by dipstick OR protein ≤ 1 g/24hr-urine collection
- INR ≤ 1.5 OR Quick ≥ 70%
- aPTT ≤ 1.5 times ULN
- No peripheral neuropathy > grade 2
- No history or evidence of hereditary bleeding diathesis or coagulopathy with the risk
of bleeding
- No uncontrolled hypertension, defined as systolic blood pressure (BP) > 150 mm Hg
and/or diastolic BP > 100 mm Hg, measured repeatedly at > 2 visits despite adequate
treatment with ≥ 2 different antihypertensive drugs
- No clinically significant cardiovascular disease, including the following:
- Cerebrovascular accident or stroke within the past 6 months
- Myocardial infarction within the past 6 months
- Unstable angina
- New York Heart Association class II-IV congestive heart failure
- Serious cardiac arrhythmia (e.g., ventricular arrhythmia, high-grade
atrioventricular-block) not controlled by medication or requiring medication
which might interfere with regularity of the study treatment
- No serious nonhealing wound, active peptic ulcer, nonhealing bone fracture, or
bleeding skin metastases
- No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within
the past 6 months
- No active infection requiring IV antibiotics
- No known hypersensitivity to any of the study drugs or excipients
- No known hypersensitivity to Chinese hamster ovary cell products or other recombinant
human or humanized antibodies
- No evidence of any other disease that contraindicates the use of an investigational
drug, that may affect patient compliance with study routines, or places the patient
at high risk for treatment-related complications including, but not limited to, the
following:
- Metabolic dysfunction
- Physical examination finding
- Psychological dysfunction
- Clinical laboratory finding giving reasonable suspicion of a disease or
condition
- No known CNS disease unrelated to cancer (e.g., uncontrolled seizures), unless
adequately treated with standard medical therapy
- No high-risk factors for bleeding, including the following:
- Coagulation parameters outside range
- Need for concurrent anticoagulant therapy
- Insufficient time gap after surgical procedures
- No other malignancy within the past 5 years except for adequately treated basal cell
or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
- No significant traumatic injury within the past 28 days
- No known HIV positivity
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 12 months after
completion of study therapy
PRIOR CONCURRENT THERAPY:
- No prior chemotherapy for metastatic or inoperable locally recurrent breast cancer
- No prior bevacizumab or other anti-vascular endothelial growth factor drug therapy
- No prior radiotherapy involving the heart (usual irradiation dose to breast or chest
wall allowed)
- More than 12 months since prior neoadjuvant or adjuvant chemotherapy
- No neoadjuvant or adjuvant doxorubicin hydrochloride with cumulative dose > 360 mg/m²
or epirubicin hydrochloride with cumulative dose > 720 mg/m²
- More than 6 months since prior adjuvant radiotherapy
- More than 28 days since prior major surgical procedure with high risk of bleeding
- More than 24 hours since prior minor surgical procedures
- More than 10 days since prior acetylsalicylic acid (> 325 mg/day) or clopidogrel
bisulfate (> 75 mg/day)
- More than 10 days since prior and no concurrent use of full-dose oral or parenteral
anticoagulants or thrombolytic agents for therapeutic purposes
- Prophylactic use of anticoagulants allowed (e.g., for maintenance of venous
catheter)
- More than 30 days since prior investigational therapies or participation in other
investigational studies
- No concurrent hormonal therapy
- No other concurrent antineoplastic or antitumor therapy
- No other concurrent investigational drugs
- No concurrent radiotherapy
- No concurrent nonsteroidal anti-inflammatory drugs with activity on platelets and
gastric mucosa (e.g., dipyridamole, clopidogrel bisulfate, acetylsalicylic acid)
- No anticipated need for major surgery during the course of the study treatment